TY - JOUR
T1 - Feasibility study of in vivo MRI based dosimetric verification of proton end-of-range for liver cancer patients
AU - Yuan, Yading
AU - Andronesi, Ovidiu C.
AU - Bortfeld, Thomas R.
AU - Richter, Christian
AU - Wolf, Russell
AU - Guimaraes, Alexander R.
AU - Hong, Theodore S.
AU - Seco, Joao
N1 - Funding Information:
The authors are grateful to Dr. Gregory C. Sharp for helpful discussion on image registration. They also thank Dr. Peter Biggs for his insightful comments on this study. This study was supported by the Federal Share of program income earned by Massachusetts General Hospital on C06-CA059267, Proton Therapy Research and Treatment Center.
PY - 2013/3
Y1 - 2013/3
N2 - Purpose: To investigate the feasibility of using MRI to verify proton beam distal range for liver tumor treatment in a retrospective study. Methods and materials: Because the follow-up hepatocyte-specific functional MR imaging can detect the radiobiological change of liver tissue after radiation, we firstly registered the contrast-enhanced MR images to the planning CT images from 5 liver patients, then overlaid the prescribed dose distribution on the MR images. Since dose calculation is most accurate at the penumbra dose region, we correlated the MR signal intensity (SI) to the radiation dose at the superior/inferior penumbra region. This dose-SI correlation was finally employed on registered MR images to estimate the proton end-of-range. Results: Statistically significant correlations between radiation dose and MR SI were observed in superior/inferior penumbra regions, with correlation coefficient ranging from 0.93 to 0.99. By applying the dose-SI correlation to the distal region of each proton beam, the mean difference between MR-estimated and the planned dose range was -2.18 ± 4.89 mm for anterior-posterior beams and -3.90 ± 5.87 mm for lateral beams. Conclusions: This feasibility study proved the principle that proton dose range can be verified in vivo by follow-up MR images after proton liver treatment.
AB - Purpose: To investigate the feasibility of using MRI to verify proton beam distal range for liver tumor treatment in a retrospective study. Methods and materials: Because the follow-up hepatocyte-specific functional MR imaging can detect the radiobiological change of liver tissue after radiation, we firstly registered the contrast-enhanced MR images to the planning CT images from 5 liver patients, then overlaid the prescribed dose distribution on the MR images. Since dose calculation is most accurate at the penumbra dose region, we correlated the MR signal intensity (SI) to the radiation dose at the superior/inferior penumbra region. This dose-SI correlation was finally employed on registered MR images to estimate the proton end-of-range. Results: Statistically significant correlations between radiation dose and MR SI were observed in superior/inferior penumbra regions, with correlation coefficient ranging from 0.93 to 0.99. By applying the dose-SI correlation to the distal region of each proton beam, the mean difference between MR-estimated and the planned dose range was -2.18 ± 4.89 mm for anterior-posterior beams and -3.90 ± 5.87 mm for lateral beams. Conclusions: This feasibility study proved the principle that proton dose range can be verified in vivo by follow-up MR images after proton liver treatment.
KW - Distal proton range verification
KW - In vivo dosimetry
KW - Liver tumor
KW - Magnetic resonance imaging
KW - Proton therapy
KW - Radiation effects on liver
UR - http://www.scopus.com/inward/record.url?scp=84876155314&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84876155314&partnerID=8YFLogxK
U2 - 10.1016/j.radonc.2013.01.016
DO - 10.1016/j.radonc.2013.01.016
M3 - Article
C2 - 23473960
AN - SCOPUS:84876155314
SN - 0167-8140
VL - 106
SP - 378
EP - 382
JO - Radiotherapy and Oncology
JF - Radiotherapy and Oncology
IS - 3
ER -